The analyst believes that Zantac litigation has "disproportionately ... attributable to misguided assumptions around the potential cost of litigation," he added. GSK's stock was up 1.6% at ...

Jessica Olah / Investopedia The activity-based costing method recognizes costs like overhead, salaries, and utilities as activity cost drivers. An activity cost driver is an action that triggers ...

Understanding your cost of living can help you stay within your budget. The cost of living varies from state to state and even city to city within a state. Cost of living calculators can be ...

GSK, its consumer health spin-off Haleon, and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it ...

Another jury in the same courthouse handed a verdict last month to a separate Zantac manufacturer, GlaxoSmithKline. On May 23, an Illinois jury sided with both drug manufacturers in the first ...

The companies, which also include Pfizer and Sanofi, are challenging a lower court ruling that allowed expert testimony claiming Zantac causes cancer – a link they say is not credible.

We continue to believe Zantac litigation has disproportionately ... attributable to misguided assumptions around the potential cost of litigation. 'Our thesis remains that GSK offers a decent ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical giants to throw out over 70,000 lawsuits ...

Pharmaceutical giant GlaxoSmithKline (GSK) and rival drug manufacturers, including Sanofi, Pfizer and Boehringer Ingelheim, have won the right to an appeal hearing by the Delaware Supreme Court ...

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...